JP2002533119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002533119A5 JP2002533119A5 JP2000591177A JP2000591177A JP2002533119A5 JP 2002533119 A5 JP2002533119 A5 JP 2002533119A5 JP 2000591177 A JP2000591177 A JP 2000591177A JP 2000591177 A JP2000591177 A JP 2000591177A JP 2002533119 A5 JP2002533119 A5 JP 2002533119A5
- Authority
- JP
- Japan
- Prior art keywords
- gpi
- pld
- nucleic acid
- polypeptide
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100032538 Phosphatidylinositol-glycan-specific phospholipase D Human genes 0.000 description 41
- 108010045724 glycoprotein phospholipase D Proteins 0.000 description 41
- 238000000034 method Methods 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 150000001413 amino acids Chemical group 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 208000002249 Diabetes Complications Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- 206010012655 Diabetic complications Diseases 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000005976 liver dysfunction Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- 102000007592 Apolipoproteins Human genes 0.000 description 2
- 108010071619 Apolipoproteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000730493 Homo sapiens Phosphatidylinositol-glycan-specific phospholipase D Proteins 0.000 description 2
- 108090000553 Phospholipase D Proteins 0.000 description 2
- 102000011420 Phospholipase D Human genes 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 208000027700 hepatic dysfunction Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- -1 label Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9828713.9 | 1998-12-24 | ||
| GBGB9828715.4A GB9828715D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d protiens and uses thereof |
| GB9828715.4 | 1998-12-24 | ||
| GB9828712.1 | 1998-12-24 | ||
| GBGB9828713.9A GB9828713D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d protiens and uses therof |
| GBGB9828712.1A GB9828712D0 (en) | 1998-12-24 | 1998-12-24 | Glycosylphosphatidylinositol specific phospholipase d proteins and usues thereof |
| PCT/GB1999/004399 WO2000039285A2 (en) | 1998-12-24 | 1999-12-23 | Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533119A JP2002533119A (ja) | 2002-10-08 |
| JP2002533119A5 true JP2002533119A5 (https=) | 2007-02-15 |
Family
ID=27269604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000591177A Pending JP2002533119A (ja) | 1998-12-24 | 1999-12-23 | グリコシルホスファチジルイノシトール特異的ホスホリパーゼｄタンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1141334B1 (https=) |
| JP (1) | JP2002533119A (https=) |
| AT (1) | ATE410516T1 (https=) |
| AU (1) | AU774986B2 (https=) |
| CA (1) | CA2355468A1 (https=) |
| DE (1) | DE69939707D1 (https=) |
| WO (1) | WO2000039285A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0015625D0 (en) * | 2000-06-26 | 2000-08-16 | Univ London | Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| GB0015986D0 (en) * | 2000-06-29 | 2000-08-23 | Univ London | Glycosylphosphatidylinositol specific phospholipase d proteins or the treatment or diagnosis of atherosclerosis |
| CA2528155A1 (en) * | 2003-06-04 | 2005-01-06 | Duke University | Compositions and methods for modulating s-nitrosoglutathione reductase |
| US9474792B2 (en) * | 2013-03-15 | 2016-10-25 | Amgen Inc. | Method of treating metabolic disorders using PLA2G12A polypeptides and PLA2G12A mutant polypeptides |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477739A3 (en) * | 1990-09-27 | 1992-12-09 | F. Hoffmann-La Roche Ag | Glycosyl-phosphatidylinositol-specific phospholipase d |
| WO1999047565A1 (en) * | 1998-03-18 | 1999-09-23 | Rademacher Group Limited | Anti-inositolphosphoglycan monoclonal antibodies |
-
1999
- 1999-12-23 DE DE69939707T patent/DE69939707D1/de not_active Expired - Fee Related
- 1999-12-23 AT AT99963641T patent/ATE410516T1/de not_active IP Right Cessation
- 1999-12-23 WO PCT/GB1999/004399 patent/WO2000039285A2/en not_active Ceased
- 1999-12-23 EP EP99963641A patent/EP1141334B1/en not_active Expired - Lifetime
- 1999-12-23 AU AU19883/00A patent/AU774986B2/en not_active Ceased
- 1999-12-23 JP JP2000591177A patent/JP2002533119A/ja active Pending
- 1999-12-23 CA CA002355468A patent/CA2355468A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7291594B2 (en) | GLP-1 derivative and preparation thereof absorbable via mucous membrane | |
| EA009377B1 (ru) | Еро-имитирующие миметические антитела человека с центральной шарнирной областью, композиции, способы и применения | |
| EA011583B1 (ru) | Миметические антитела glp-1 человека, композиции, способы и применения | |
| JPH07504670A (ja) | ペプチドの使用 | |
| RU2684398C2 (ru) | Состав с постоянным соотношением инсулина гларгина/ликсизенатида | |
| JP2010031018A5 (https=) | ||
| JP2017529326A5 (https=) | ||
| WO2012096411A1 (ja) | 難治性炎症性腸疾患の予防又は治療方法 | |
| RU2426745C2 (ru) | Рекомбинантный химерный белок фактора ингибирования нейтрофилов и гиругена и содержащая его фармацевтическая композиция | |
| JPS63303930A (ja) | インシユリンおよびインシユリン誘導体の混合結晶 | |
| US20240343773A1 (en) | Glucose-responsive insulin analogs and methods of use thereof | |
| JP2002533119A5 (https=) | ||
| CN120114574B (zh) | 重组iii型人源化胶原蛋白在胃癌产品中的新用途 | |
| CN106552259B (zh) | 一种融合蛋白及其治疗疾病的用途 | |
| JP2008502323A5 (https=) | ||
| JPH0859492A (ja) | 抗糖尿病薬 | |
| WO2017186088A1 (zh) | 小分子透明质酸片段的应用 | |
| CN119639704B (zh) | 重组球形节杆菌尿酸酶及其应用 | |
| AU2020256316B2 (en) | Molecular design of recombinant protein drug | |
| EP4667498A1 (en) | Glp-1 analog-fc fusion protein and use thereof | |
| US20230263856A1 (en) | Compositions and methods for treating diabetes, hypertension and hypercholesterolemia | |
| KR101191613B1 (ko) | 파라옥소나아제 함유 제제 | |
| JP2002080395A (ja) | 心筋傷害処置剤 | |
| EP1243275A1 (en) | Insulin-containing medicament for peroral application and method for the production thereof | |
| JP2001098000A5 (https=) |